It is estimated that 400 million people suffer from a rare disease globally, with approximately 7,000 distinct types of rare and genetic diseases identified. On average, it takes eight years before rare disease patients receive an accurate diagnosis and even then, the majority of those diagnosed lack access to approved therapies for targeted treatment. Many of these rare diseases affect children, with irreversible debilitating and painful impact that is often fatal. Thus, it is essential to identify patients early and connect them to treatment as soon as possible to improve patient outcomes.
Prioritising Alzheimer’s disease policy in Europe: Insights from oncology
However, current levels of policy development do not reflect the urgency for change, especially given the progress made in understanding the disease and new...